{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:06:38Z","timestamp":1785240398208,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.019","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:12:09Z","timestamp":1777306329000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Management of High-Risk Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Walid","family":"Macaron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.clml.2026.04.019_bib0001","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"386","author":"Fo\u00e0","year":"2022","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2026.04.019_bib0002","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMra2405573","article-title":"Ph-positive acute lymphoblastic leukemia: 25 years of progress","volume":"392","author":"Fo\u00e0","year":"2025","journal-title":"New Engl J Med"},{"issue":"10506","key":"10.1016\/j.clml.2026.04.019_bib0003","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","article-title":"Acute lymphocytic leukaemia","volume":"406","author":"Kantarjian","year":"2025","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.clml.2026.04.019_bib0004","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/cncr.33529","article-title":"Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.clml.2026.04.019_bib0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.019_bib0006","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.clml.2026.04.019_bib0007","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs Imatinib in frontline Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.clml.2026.04.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"issue":"36","key":"10.1016\/j.clml.2026.04.019_bib0009","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of Ponatinib and Blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.clml.2026.04.019_bib0010","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the Dasatinib-Blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.019_bib0011","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","article-title":"Molecular characterization and predictors of relapse in patients with ph\u2009+\u2009ALL after frontline ponatinib and blinatumomab","volume":"18","author":"Short","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.clml.2026.04.019_bib0013","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.04.019_bib0014","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","article-title":"A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.019_bib0015","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-3343","article-title":"SWOG 1318: combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes","volume":"146","author":"Advani","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.04.019_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2026.04.019_bib0017","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of measurable residual disease in adult Philadelphia chromosome\u2013Positive ALL: a GRAAPH-2014 study","volume":"42","author":"Kim","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.04.019_bib0018","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41409-021-01422-7","volume":"56","author":"Akahoshi","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2026.04.019_bib0019","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24625","article-title":"Poor outcomes associated with +der(22)t(9;22) and \u22129\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.019_bib0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/10428194.2017.1326596","article-title":"Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia","volume":"59","author":"Motll\u00f3","year":"2018","journal-title":"Leukemia Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2026.04.019_bib0021","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2141.1996.d01-1968.x","article-title":"Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia","volume":"95","author":"Rieder","year":"1996","journal-title":"Br J Haematol"},{"issue":"31","key":"10.1016\/j.clml.2026.04.019_bib0022","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) deletions in BCR-ABL1\u2013positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.04.019_bib0023","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2017-07-796862","article-title":"Genomic CDKN2A\/2B deletions in adult ph+ ALL are adverse despite allogeneic stem cell transplantation","volume":"131","author":"Pfeifer","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2026.04.019_bib0024","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-11-1227","article-title":"CDKN2A\/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients","volume":"17","author":"Iacobucci","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2026.04.019_bib0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/07853890.2018.1564359","article-title":"Prognostic significance of CDKN2A\/B deletions in acute lymphoblastic leukaemia: a meta-analysis","volume":"51","author":"Zhang","year":"2019","journal-title":"Ann Med"},{"issue":"12","key":"10.1016\/j.clml.2026.04.019_bib0026","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus Defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.019_bib0027","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s41375-021-01496-8","article-title":"Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib","volume":"36","author":"Sasaki","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2026.04.019_bib0028","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia\u2014from intensive chemotherapy combinations to chemotherapy-free regimens: a review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2026.04.019_bib0029","unstructured":"NCCN. Accessed April 20, 2025. NCCN guidelines. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1410."},{"issue":"1","key":"10.1016\/j.clml.2026.04.019_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26622","article-title":"Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"98","author":"Paul","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.019_bib0031","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jamaoncol.2025.0613","article-title":"Management of adult acute lymphoblastic leukemia: a review","volume":"11","author":"Kantarjian","year":"2025","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.019_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.04.019_bib0033","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood."},{"issue":"20","key":"10.1016\/j.clml.2026.04.019_bib0034","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.04.019_bib0035","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.clml.2026.04.019_bib0036","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.clml.2026.04.019_bib0037","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.04.019_bib0038","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2026.04.019_bib0039","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-020-0329-y","article-title":"Ultra-accurate duplex sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL","volume":"10","author":"Short","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2026.04.019_bib0040","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/bjh.19804","article-title":"Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed\/refractory disease","volume":"205","author":"Liu","year":"2024","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.clml.2026.04.019_bib0041","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013Positive B-precursor acute lymphoblastic leukemia following treatment with Blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.04.019_bib0042","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.019_bib0043","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-439","article-title":"First results of the phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients","volume":"146","author":"Chiaretti","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.04.019_bib0044","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2025.0674","article-title":"Dasatinib and CAR T-cell therapy in newly diagnosed Philadelphia chromosome\u2013Positive acute lymphoblastic leukemia: a nonrandomized clinical trial","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.019_bib0045","article-title":"Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: a prospective phase 2 study","volume":"146","author":"Gu","year":"2025","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2026.04.019_bib0046","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of Ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"New Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:57:30Z","timestamp":1785239850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001308"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Management of High-Risk Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}